OBJECTIVE: To establish the drug evaluation criteria of ceftazidime and find out the problems in current clinical application

so as to provide reference for clinical rational application. METHODS: According to the dispensatory

clinical guideline and consensus of ceftazidime

the evaluation rules of ceftazidine were formulated combined with relevant literature. Totally 120 archived medical records with ceftazidime treatment from Jul. to Dec. 2021 were collected and evaluated for drug utilization by using the weighted TOPSIS method. RESULTS: Among the secondary indicators

the relative weight of disease diagnosis took the lead

and the solvent selection and solvent configuration ranked last. Among the 120 medical records

there were 22 medical records（18.33%） with C

i

>

0.9

17 medical records（14.17%） with C

i

>

0.8 to 0.9

45 medical records（37.50%） with C

i

>

0.7 to 0.8

25 medical records（20.83%） with C

i

>

0.6 to 0.7

and 11 medical records（9.17%） with C

i

≤0.6. Of the 15 clinical departments

12 had mean C

i

in the good range（from 0.7 to 0.9）

while the orthopedics

neurosurgery

and general surgery departments had low mean C

i

. The irrational application of ceftazidime in the hospital was mainly focused on the dose administered. CONCLUSIONS: The comprehensive evaluation on the rationality of ceftazidime application by using the weighted TOPSIS method is feasible

and the evaluation results are objective. Through the analysis on the results

it can be intuitively seen that the application of ceftazidime in this hospital is mostly reasonable

but there are still some problems. Based on the results of the review

to further strengthen the regulation of rational drug application.